Friend, Promoting safe, equitable, and effective access to vaccines is a top priority for ADB’s COVID-19 response efforts. It is also addressing the impacts of the pandemic and streamlined some procedures to deliver quicker and more flexible assistance.
Recently, ADB has launched a $9 billion COVID-19 vaccine initiative — the Asia Pacific Vaccine Access Facility (APVAX) to procure vaccines as well as appropriate plans and knowledge to be able to safely, equitably, and efficiently manage the vaccination process.
APVAX will play a critical role in helping our developing members meet these challenges, overcome the pandemic, and focus on economic recovery. ADB financing for vaccines will be provided in close coordination with other development partners including the World Bank Group, World Health Organization (WHO), COVID-19 Vaccines Global Access Facility (COVAX), GAVI, and bilateral and multilateral partners.
ADB is also making available a $500 million Vaccine Import Facility to support the efforts of its developing members to secure safe and effective vaccines, as well as the goods that support distribution and inoculation.
